392 related articles for article (PubMed ID: 11156402)
61. Increased non-major histocompatibility complex-restricted lytic activity in melanoma patients vaccinated with cytokine gene-transfected autologous tumor cells.
Möller P; Möller H; Sun Y; Dorbic T; Henz BM; Wittig B; Schadendorf D
Cancer Gene Ther; 2000 Jul; 7(7):976-84. PubMed ID: 10917199
[TBL] [Abstract][Full Text] [Related]
62. Gene transfer to dendritic cells induced a protective immunity against melanoma.
Metharom P; Ellem KA; Wei MQ
Cell Mol Immunol; 2005 Aug; 2(4):281-8. PubMed ID: 16274626
[TBL] [Abstract][Full Text] [Related]
63. DC-expressed MHC class I single-chain trimer-based vaccines prime cytotoxic T lymphocytes against exogenous but not endogenous antigens.
Ordaz ML; Larmonier N; Lybarger L
Cell Immunol; 2010; 262(2):141-9. PubMed ID: 20199770
[TBL] [Abstract][Full Text] [Related]
64. Antigen-containing liposomes engrafted with flagellin-related peptides are effective vaccines that can induce potent antitumor immunity and immunotherapeutic effect.
Faham A; Altin JG
J Immunol; 2010 Aug; 185(3):1744-54. PubMed ID: 20610649
[TBL] [Abstract][Full Text] [Related]
65. Ubiquitin-fusion degradation pathway plays an indispensable role in naked DNA vaccination with a chimeric gene encoding a syngeneic cytotoxic T lymphocyte epitope of melanocyte and green fluorescent protein.
Zhang M; Ishii K; Hisaeda H; Murata S; Chiba T; Tanaka K; Li Y; Obata C; Furue M; Himeno K
Immunology; 2004 Aug; 112(4):567-74. PubMed ID: 15270727
[TBL] [Abstract][Full Text] [Related]
66. Vaccine Trials for the Clinician: Prospects for Tumor Antigens.
Osanto S
Oncologist; 1997; 2(5):284-299. PubMed ID: 10388061
[TBL] [Abstract][Full Text] [Related]
67. Genetic immunization of mice with human tyrosinase-related protein 2: implications for the immunotherapy of melanoma.
Steitz J; Brück J; Steinbrink K; Enk A; Knop J; Tüting T
Int J Cancer; 2000 Apr; 86(1):89-94. PubMed ID: 10728600
[TBL] [Abstract][Full Text] [Related]
68. Therapeutic effect of dendritic cells loaded with a fusion mRNA encoding tyrosinase-related protein 2 and enhanced green fluorescence protein on B16 melanoma.
Fukui M; Nakano-Hashimoto T; Okano K; Maruta Y; Suehiro Y; Hamanaka Y; Yamashita H; Imai K; Kawano MM; Hinoda Y
Tumour Biol; 2004; 25(5-6):252-7. PubMed ID: 15627888
[TBL] [Abstract][Full Text] [Related]
69. Murine tyrosinase expressed by a T7 vector in bone marrow-derived dendritic progenitors effectively prevents and eradicates melanoma tumors in mice.
Li J; Holmes LM; Franek KJ; Wagner TE; Wei Y
Cancer Gene Ther; 2000 Nov; 7(11):1448-55. PubMed ID: 11129287
[TBL] [Abstract][Full Text] [Related]
70. Specific peptide-mediated immunity against established melanoma tumors with dendritic cells requires IL-2 and fetal calf serum-free cell culture.
Eggert AO; Becker JC; Ammon M; McLellan AD; Renner G; Merkel A; Bröcker EB; Kämpgen E
Eur J Immunol; 2002 Jan; 32(1):122-7. PubMed ID: 11754352
[TBL] [Abstract][Full Text] [Related]
71. Identification and characterization of survivin-derived H-2Kb-restricted CTL epitopes.
Hofmann UB; Voigt H; Andersen MH; Straten PT; Becker JC; Eggert AO
Eur J Immunol; 2009 May; 39(5):1419-24. PubMed ID: 19337999
[TBL] [Abstract][Full Text] [Related]
72. Particulate naturally processed peptides prime a cytotoxic response against human melanoma in vitro.
Protti MP; Imro MA; Manfredi AA; Consogno G; Heltai S; Arcelloni C; Bellone M; Dellabona P; Casorati G; Rugarli C
Cancer Res; 1996 Mar; 56(6):1210-3. PubMed ID: 8640799
[TBL] [Abstract][Full Text] [Related]
73. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.
Goldszmid RS; Idoyaga J; Bravo AI; Steinman R; Mordoh J; Wainstok R
J Immunol; 2003 Dec; 171(11):5940-7. PubMed ID: 14634105
[TBL] [Abstract][Full Text] [Related]
74. Biolistic DNA vaccination against melanoma.
Steitz J; Tüting T
Methods Mol Biol; 2013; 940():317-37. PubMed ID: 23104352
[TBL] [Abstract][Full Text] [Related]
75. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
[TBL] [Abstract][Full Text] [Related]
76. Efficient nonviral transfection of dendritic cells and their use for in vivo immunization.
Irvine AS; Trinder PK; Laughton DL; Ketteringham H; McDermott RH; Reid SC; Haines AM; Amir A; Husain R; Doshi R; Young LS; Mountain A
Nat Biotechnol; 2000 Dec; 18(12):1273-8. PubMed ID: 11101806
[TBL] [Abstract][Full Text] [Related]
77. Long peptide vaccination can lead to lethality through CD4+ T cell-mediated cytokine storm.
Kitamura H; Sedlik C; Jacquet A; Zaragoza B; Dusseaux M; Premel V; Sastre-Garau X; Lantz O
J Immunol; 2010 Jul; 185(2):892-901. PubMed ID: 20543102
[TBL] [Abstract][Full Text] [Related]
78. Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma.
Bellone M; Cantarella D; Castiglioni P; Crosti MC; Ronchetti A; Moro M; Garancini MP; Casorati G; Dellabona P
J Immunol; 2000 Sep; 165(5):2651-6. PubMed ID: 10946294
[TBL] [Abstract][Full Text] [Related]
79. Identification of immunogenic B16 melanoma-associated antigens.
Johnston D; Schachne JP; Bystryn JC
J Biol Response Mod; 1987 Apr; 6(2):108-20. PubMed ID: 3585408
[TBL] [Abstract][Full Text] [Related]
80. Mouse melanoma antigen recognized by Lyt-2- and L3T4- cytotoxic T-lymphocytes.
Ono K; Takahashi K; Hirabayashi Y; Itoh T; Hiraga Y; Taniguchi M
Cancer Res; 1988 May; 48(10):2730-3. PubMed ID: 2452012
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
